药物涂层球囊血管成形术对慢性肢体威胁性缺血伤口愈合的作用
RADISH多中心回顾性研究纳入927例股腘动脉病变的慢性肢体威胁性缺血患者,比较药物涂层球囊(DCB)与非DCB治疗。倾向性评分匹配后,两组1年伤口愈合累积发生率无显著差异(74.4% vs 71.9%,p=0.93),但DCB组一期通畅率更高(p=0.002)、免于临床驱动靶病变血运重建率更高(p=0.010)。
要点
- DCB治疗未延迟CLTI患者股腘动脉病变的伤口愈合。
- DCB组一期通畅率和免于CD-TLR优于非DCB组。
- 两组肢体挽救和总生存无显著差异。
核心结论
- DCB治疗未导致CLTI患者股腘动脉病变伤口愈合延迟,并降低再狭窄率。
研究设计与样本
- 多中心回顾性研究,纳入927例CLTI合并股腘动脉病变患者,平均年龄76±10岁,男性57.8%,糖尿病64.5%,透析50.7%。
- 2014年4月至2019年3月期间接受DCB治疗138例,非DCB治疗789例。
主要发现
- 倾向性评分匹配提取111对(DCB组111例,非DCB组629例)。
- 1年伤口愈合累积发生率DCB组74.4%(95%CI 62.6%-82.5%),非DCB组71.9%(95%CI 60.4%-80.1%),组间无显著差异(p=0.93)。
- DCB组一期通畅率高于非DCB组(p=0.002)。
- DCB组免于CD-TLR率高于非DCB组(p=0.010)。
- 肢体挽救(p=0.21)和总生存(p=0.93)组间无显著差异。
关键数值与推荐
- 主要结局为1年伤口愈合,次要结局为1年一期通畅率。
- 倾向性评分匹配后DCB组111例,非DCB组629例。
临床怎么用
- 对于CLTI合并股腘动脉病变患者,DCB治疗可作为合理选择,不延迟伤口愈合且减少再狭窄。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical trials have demonstrated sustained benefits of drug-coated balloon (DCB) angioplasty compared with noncoated balloon angioplasty in symptomatic peripheral artery disease (PAD) presenting with femoropopliteal (FP) artery disease. However, there is still controversy whether particulate embolization caused by crystalline paclitaxel, the so-called "downstream effect," is adversely associated with clinical outcomes after use of FP DCB among chronic limb-threatening ischemia (CLTI) patients. The current RADISH (Roles of Angioplasty with Drug-coated balloon for chronic ISchemia in wound Healing) study investigated wound healing following DCB therapy vs non-DCB therapy for real-world CLTI patients presenting with FP lesions. MATERIALS AND METHODS: This multicenter, retrospective study analyzed 927 patients with CLTI (mean age, 76±10 years; male, 57.8%; diabetes mellitus, 64.5%; dialysis, 50.7%) presenting with FP lesions and treated endovascularly via DCB (138 patients) vs non-DCB therapy (789 patients) between April 2014 and March 2019. The primary outcome measure was 1-year wound healing, while the secondary outcome measure was 1-year primary patency. Clinically-driven target lesion revascularization (CD-TLR), limb salvage and overall survival were also analyzed by using propensity score matching analysis. RESULTS: The propensity score matching extracted 111 pairs (as many patients in the DCB group and 629 patients in the non-DCB group). The 1-year cumulative incidence of wound healing (95% CI) was 74.4% (62.6% to 82.5%) in the DCB group and 71.9% (60.4% to 80.1%) in the non-DCB group, with no significant intergroup difference (p=0.93). The DCB group had a higher rate of primary patency (p=0.002) and freedom from CD-TLR (p=0.010) than the non-DCB group, whereas there was no significant intergroup difference in limb salvage (p=0.21) or overall survival (p=0.93). CONCLUSION: The current analysis of data from the RADISH study demonstrated that DCB therapy did not lead to delayed wound healing and reduced restenosis rate in CLTI patients presenting FP lesions. From this results, DCB therapy would be a reasonable treatment option for CLTI patients.
引用
- Hata Y, Iida O, Ito N, et al. Roles of Angioplasty With Drug-Coated Balloon for Chronic Ischemia in Wound Healing. J Endovasc Ther. 2021. PMID: 34152229. doi:10.1177/15266028211025023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。